MX2017014731A - Eliminacion de linfocitos b como marcador diagnostico. - Google Patents
Eliminacion de linfocitos b como marcador diagnostico.Info
- Publication number
- MX2017014731A MX2017014731A MX2017014731A MX2017014731A MX2017014731A MX 2017014731 A MX2017014731 A MX 2017014731A MX 2017014731 A MX2017014731 A MX 2017014731A MX 2017014731 A MX2017014731 A MX 2017014731A MX 2017014731 A MX2017014731 A MX 2017014731A
- Authority
- MX
- Mexico
- Prior art keywords
- lymphocytes
- removal agent
- methods
- administration
- elimination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
En general, la presente invención hace referencia al campo de tratamientos médicos y marcadores diagnósticos, y, más específicamente, a métodos y usos para el tratamiento de leucemia linfocítica aguda (LLA) que involucran la administración de un agente de eliminación de linfocitos B. También se vislumbran usos y métodos para mantener o aumentar la cantidad de supervivientes a largo plazo de LLA. Los usos y métodos provistos en la presente comprenden la administración de un agente de eliminación de linfocitos B y/o el ajuste de la dosis o el régimen de tratamiento del agente de eliminación de linfocitos B, de forma que la cantidad de linfocitos B en la sangre de los pacientes tratados se mantenga o se reduzca a menos de un linfocito B/ml de suero en un período de tiempo predefinido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164278P | 2015-05-20 | 2015-05-20 | |
| PCT/EP2016/061179 WO2016184931A1 (en) | 2015-05-20 | 2016-05-19 | B-cell depletion as a diagnostic marker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017014731A true MX2017014731A (es) | 2018-06-28 |
Family
ID=56119449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014731A MX2017014731A (es) | 2015-05-20 | 2016-05-19 | Eliminacion de linfocitos b como marcador diagnostico. |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP3298042B1 (es) |
| JP (1) | JP7156793B2 (es) |
| AU (1) | AU2016263464B2 (es) |
| CA (1) | CA2980827A1 (es) |
| DK (1) | DK3298042T3 (es) |
| ES (1) | ES3010637T3 (es) |
| FI (1) | FI3298042T3 (es) |
| HR (1) | HRP20250112T1 (es) |
| HU (1) | HUE070100T2 (es) |
| LT (1) | LT3298042T (es) |
| MX (1) | MX2017014731A (es) |
| PL (1) | PL3298042T3 (es) |
| PT (1) | PT3298042T (es) |
| RS (1) | RS66511B1 (es) |
| SI (1) | SI3298042T1 (es) |
| SM (1) | SMT202500091T1 (es) |
| WO (1) | WO2016184931A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA51210A (fr) * | 2017-12-01 | 2020-10-07 | Juno Therapeutics Inc | Procédés de dosage et de modulation de cellules génétiquement modifiées |
| JP7410143B2 (ja) * | 2018-11-01 | 2024-01-09 | 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 | 二重特異性抗体及びその用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| KR101695327B1 (ko) | 2008-11-07 | 2017-01-11 | 암젠 리서치 (뮌헨) 게엠베하 | 급성 림프구성 백혈병의 치료방법 |
| PL2918604T3 (pl) | 2008-11-07 | 2018-05-30 | Amgen Research (Munich) Gmbh | Leczenie pediatrycznej ostrej białaczki limfoblastycznej |
-
2016
- 2016-05-19 AU AU2016263464A patent/AU2016263464B2/en active Active
- 2016-05-19 WO PCT/EP2016/061179 patent/WO2016184931A1/en not_active Ceased
- 2016-05-19 MX MX2017014731A patent/MX2017014731A/es unknown
- 2016-05-19 RS RS20250155A patent/RS66511B1/sr unknown
- 2016-05-19 LT LTEPPCT/EP2016/061179T patent/LT3298042T/lt unknown
- 2016-05-19 SM SM20250091T patent/SMT202500091T1/it unknown
- 2016-05-19 HR HRP20250112TT patent/HRP20250112T1/hr unknown
- 2016-05-19 SI SI201631887T patent/SI3298042T1/sl unknown
- 2016-05-19 PT PT167286202T patent/PT3298042T/pt unknown
- 2016-05-19 HU HUE16728620A patent/HUE070100T2/hu unknown
- 2016-05-19 EP EP16728620.2A patent/EP3298042B1/en active Active
- 2016-05-19 FI FIEP16728620.2T patent/FI3298042T3/fi active
- 2016-05-19 ES ES16728620T patent/ES3010637T3/es active Active
- 2016-05-19 EP EP24218475.2A patent/EP4523759A3/en active Pending
- 2016-05-19 JP JP2017557044A patent/JP7156793B2/ja active Active
- 2016-05-19 DK DK16728620.2T patent/DK3298042T3/da active
- 2016-05-19 CA CA2980827A patent/CA2980827A1/en active Pending
- 2016-05-19 PL PL16728620.2T patent/PL3298042T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3298042T (lt) | 2025-02-10 |
| SMT202500091T1 (it) | 2025-03-12 |
| EP4523759A2 (en) | 2025-03-19 |
| PL3298042T3 (pl) | 2025-04-28 |
| CA2980827A1 (en) | 2016-11-24 |
| SI3298042T1 (sl) | 2025-03-31 |
| EP3298042B1 (en) | 2024-12-11 |
| RS66511B1 (sr) | 2025-03-31 |
| FI3298042T3 (fi) | 2025-02-26 |
| DK3298042T3 (da) | 2025-02-24 |
| JP7156793B2 (ja) | 2022-10-19 |
| EP3298042A1 (en) | 2018-03-28 |
| HUE070100T2 (hu) | 2025-05-28 |
| EP4523759A3 (en) | 2025-06-11 |
| JP2018517681A (ja) | 2018-07-05 |
| AU2016263464A1 (en) | 2018-01-04 |
| HRP20250112T1 (hr) | 2025-03-28 |
| PT3298042T (pt) | 2025-02-21 |
| ES3010637T3 (en) | 2025-04-04 |
| AU2016263464B2 (en) | 2021-12-23 |
| WO2016184931A1 (en) | 2016-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020006009A2 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos | |
| CL2017000156A1 (es) | Procedimientos para el tratamiento de paramixovirus. | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| CO2017010260A2 (es) | Un dispositivo para la reducción de oxígeno en sangre y método para preparar sangre con oxígeno reducido | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| CY1122185T1 (el) | Ιατρικη χρηση ενωσεων αρτεμισινινης και αγωνιστων γεφυρινης | |
| MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
| BR112017024091A2 (pt) | métodos para o armazenamento de sangue total e composições do mesmo | |
| DOP2015000300A (es) | Compuestos de pirimidinodiona contra estados cardíacos | |
| BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
| MX2013002207A (es) | Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13. | |
| GT201700163A (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd) | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX2021007942A (es) | Metodos y sistemas para proporcionar un regimen de tratamiento personalizado de cannabinoides. | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| MX2018015022A (es) | Métodos para el tratamiento de la enfermedad de alzheimer. | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| MX2018014973A (es) | Combinaciones farmaceuticas. | |
| MX2015012444A (es) | Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos. | |
| CL2018002734A1 (es) | Métodos de tratamiento con vitamina d | |
| MX2017014257A (es) | Metodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con celulas t. | |
| CO2024007220A2 (es) | Compuestos que contienen heteroátomos y usos de estos | |
| MX2018002816A (es) | Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t. | |
| MX2017014731A (es) | Eliminacion de linfocitos b como marcador diagnostico. |